Empagliflozin restores cardiac function in obese-diabetic HFpEF mice but further alters gene expression
{{output}}
Effective treatments for heart failure with preserved ejection fraction (HFpEF) are limited. Empagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, provides cardiovascular benefits for patients with HFpEF. SGLT2 expression is virtually absent in ca... ...
